Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) — Stella

Recruiting

Back to Salivary Gland Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Singapore

National University Cancer Institute Singapore, Singapore

Key details

Phase

Safety & dosing

Sponsor

National University Hospital, Singapore

Collaborators

Gilead Sciences

Enrollment target

~32 participants

Started

April 2025

Primary completion

April 2030

Age range

21 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov